{"schema_version":"secwatch.filing_event.v1","accession":"0001737287-24-000040","form_type":"8-K","ticker":"ALLO","cik":"0001737287","company_name":"Allogene Therapeutics, Inc.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.818262+00:00","generated_at":"2026-06-02T02:30:45.273907+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Allogene expands CD19 rights to EU/UK; Q1 net loss $65M; cash $397M into 2026","bullets":["Expanded CD19 oncology rights to all EU Member States and UK from Servier; combined market opportunity increased to >$9.5B from $6B.","Q1 2024 net loss of $65.0M ($0.38 per share); R&D expenses $52.3M, G&A $17.3M.","Cash, cash equivalents, and investments $397.3M as of March 31, 2024; cash runway expected into 2026.","Pivotal Phase 2 ALPHA3 trial for cema-cel in 1L LBCL to start mid-2024; primary EFS data readout expected 2H 2026.","Initial data from Phase 1 cema-cel CLL trial expected by YE 2024; ALLO-329 IND planned Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001737287-24-000040","json":"https://secwatch.observer/filing/0001737287-24-000040.json","markdown":"https://secwatch.observer/filing/0001737287-24-000040.md","text":"https://secwatch.observer/filing/0001737287-24-000040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737287/000173728724000040/0001737287-24-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737287/000173728724000040/allo-20240513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:30:45.273907+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a9c25908bb65e09dc37274c1275539619f237b8f","claim":"Allogene Therapeutics, Inc. reported financial results for the quarter ended March 31, 2024.","evidence_excerpt":"Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended March 31, 2024 in the press release attached hereto as Exhibit 99.1","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737287/000173728724000040/0001737287-24-000040-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}